AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$6.10 USD
-0.27 (-4.24%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $6.10 0.00 (0.00%) 6:12 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.10 USD
-0.27 (-4.24%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $6.10 0.00 (0.00%) 6:12 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
Zacks News
Bio-Rad (BIO) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Bio-Rad's (BIO) solid revenue growth in geographies like Americas and Asia Pacific in Q4 buoys optimism.
Patterson Companies (PDCO) Earnings Match Estimates in Q3
by Zacks Equity Research
Patterson Companies (PDCO) gains from solid segmental contributions in Q3.
Amedisys (AMED) Tops Earnings and Revenue Estimates in Q4
by Zacks Equity Research
At the Home Health and Hospice divisions, Amedisys (AMED) gains from growth in Medicare and non-Medicare revenues in Q4.
Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall
by Zacks Equity Research
Orthofix (OFIX) revenues across majority product lines witness year-over-year growth.
New Strong Buy Stocks for February 28th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Tandem (TNDM) Posts Earnings in Q4, Revenues Top Estimates
by Zacks Equity Research
The roll-out of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales, as well as the international launch, drive Tandem's (TNDM) Q4 revenues.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
The year-over-year improvement in Insulet's (PODD) Q4 results on solid uptake of Omnipod system in the United States is encouraging. The company also gains from direct European operations.
Fresenius Medical (FMS) Earnings Beat, Revenues Miss in Q4
by Zacks Equity Research
Fresenius Medical (FMS) sees higher Q4 revenues in EMEA and Asia Pacific regions.
Masimo (MASI) Q4 Earnings and Revenues Beat, Guidance Solid
by Zacks Equity Research
Masimo (MASI) sees an increase in shipments of noninvasive technology in Q4.
Teleflex (TFX) Q4 Earnings Miss Estimates, Margins Rise
by Zacks Equity Research
In Q4, Teleflex (TFX) registers strong growth in PICC, visual navigation products and EZ-IO.
Integra's (IART) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Strength in the U.S. Codman Specialty Surgical business drives Integra LifeSciences' (IART) top line in Q4.
DexCom's (DXCM) Q4 Earnings Beat, International Revenues Up
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2018 results benefit from strong contributions from the Sensor, Transmitter and Receiver segments.
Chemed (CHE) Q4 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
Chemed's (CHE) Q4 revenues grow across key segments.
Allscripts (MDRX) Q4 Earnings Lag Estimates, Bookings Up Y/Y
by Zacks Equity Research
Significant year-over-year rise in bookings favors Allscripts' (MDRX) fourth-quarter 2018 results.
Integer Holdings' (ITGR) Q4 Earnings Beat, '19 View Strong
by Zacks Equity Research
Integer Holdings (ITGR) gains from the core Medical Sales segment's impressive performance in fourth-quarter 2018.
NuVasive (NUVA) Q4 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
NuVasive (NUVA) reports growth in revenues across all key operating segments in the fourth quarter of 2018.
Genomic Health (GHDX) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Genomic Health's (GHDX) year-over-year rise in revenues, driven by a solid uptick in the United States and internationally, makes us optimistic about the stock.
CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition holds immense promise.
Henry Schein's (HSIC) Q4 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
Strength in Henry Schein's (HSIC) global Medical and Technology and Value-added Services businesses in Q4 is encouraging.
Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down
by Zacks Equity Research
Medtronic (MDT) demonstrates improved performances at CER based on growth in most of the business segments and all geographies.
Ecolab (ECL) Earnings and Revenues Match Estimates in Q4
by Zacks Equity Research
Ecolab (ECL) sees solid segmental gains in Q4.
Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4
by Zacks Equity Research
Cryolife (CRY) revenues increase year over year across all geographies and major segments.
Quidel (QDEL) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Quidel's (QDEL) flagship Triage sees strong growth in China in Q4.
Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down
by Zacks Equity Research
In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.
Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
Bio-Techne (TECH) sees increase in revenues across key segments.